[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513628":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":38,"collaborators":7,"id":40,"slug":7,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","chidamide","This subset of patients received chidamide as first-line maintenance therapy.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"wei xu","CONTACT","+862568302182","xuwei10000@hotmail.com",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Hematological Department, People's Hospital of Jiangsu Province","RECRUITING","Nanjing","Jiangsu","210029","China","CN",{"type":29,"coordinates":30},"Point",[31,32],118.77778,32.06167,{"lat":32,"lon":31},[35],{"name":36,"role":16,"phone":37,"phoneExt":7,"email":18},"Wei Xu, PhD","+86-2568302182",{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100513628",false,"NCT05967949","A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.","A Retrospective (Non-interventional) Clinical Study on the First-line Maintenance Treatment of Peripheral T-cell Lymphoma (PTCL) With Chidamide.","Inclusion Criteria:\n\n* (1) Age: 18 years and older; (2) Gender: Male\u002FFemale; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment.\n\nExclusion Criteria:\n\n* (1) Patients with other types of lymphomas; (2) Pregnant women.","ALL","18 Years",{"count":49,"type":50},200,"ESTIMATED","OBSERVATIONAL","The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.",[54],"PTCL",[11,56],"maintenance treatment","2023-07-23",{"date":59,"type":60},"2023-08-01","ACTUAL",{"date":62,"type":60},"2023-04-01",{"date":64,"type":50},"2028-04-01",{"name":5,"class":6},1]